Adherence to bisphosphonate treatment by elderly women

Menopause. 2008 Sep-Oct;15(5):984-90. doi: 10.1097/gme.0b013e31816be98a.

Abstract

Objective: The aim of this study was to evaluate the relationship between adherence to bisphosphonate treatment by postmenopausal women and demographic, health, and lifestyle factors before treatment in a country with universal subsidies for pharmaceutical costs.

Design: Older women participating in the Australian Longitudinal Study on Women's Health who consented to linkage to Pharmaceutical Benefits Scheme claims data were included if they filled a bisphosphonate prescription between 2002 and 2005 after a medication-free interval of 180 days (N = 788). A Cox proportional hazards model was used to assess the association of baseline variables with duration of adherence to bisphosphonate treatment.

Results: The median time until discontinuation of bisphosphonate treatment was 170 days (95% CI: 154-186). Accounting for socioeconomic status, the baseline variables that were associated with adherence failure were use of acid-related medications (hazard ratio = 1.25, 95% CI: 1.01-1.55) and smoking (hazard ratio = 1.82, 95% CI: 1.26-2.64); reporting high levels of physical activity was associated with better adherence (HR = 0.69, 95% CI: 0.52-0.92).

Conclusions: Overall adherence to bisphosphonate treatment among older Australian women with a fracture history was poor. Inquiring about acid-related disorders and health behavior such as smoking and lack of physical activity could help the prescribing physician to identify women at risk of nonadherence.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Bone Density Conservation Agents / administration & dosage*
  • Bone Density Conservation Agents / economics
  • Diphosphonates / administration & dosage*
  • Diphosphonates / economics
  • Female
  • Health Behavior*
  • Humans
  • Life Style
  • Medication Adherence / statistics & numerical data*
  • Middle Aged
  • Osteoporosis, Postmenopausal / drug therapy*
  • Osteoporosis, Postmenopausal / economics
  • Patient Acceptance of Health Care / statistics & numerical data
  • Proportional Hazards Models
  • Queensland / epidemiology
  • Self Administration / statistics & numerical data
  • Women's Health*

Substances

  • Bone Density Conservation Agents
  • Diphosphonates